The research team, led by Zhilan Zhang and Ping Zhou of Xiangya Hospital of Central South University together with colleagues at Central South University Xiangya School of Medicine Affiliated Haikou Hospital, began by examining human hepatocellular carcinoma samples. They found that several immune-related molecules were prominently expressed in tumor tissue: LAG-3, an inhibitory receptor expressed on exhausted T cells; CXCL10, a chemokine secreted in response to inflammatory signals; CXCR3, the receptor on T cells that binds CXCL10; and CD8, the defining marker of cytotoxic T lymphocytes. This molecular signature hinted that the CXCL10/CXCR3 axis, a well-known trafficking pathway that guides activated T cells into inflamed tissue, was active in the liver tumor microenvironment, and that LAG-3-mediated suppression might be restraining the very T cells the pathway was drawing in.

To test the functional significance of these observations, the investigators turned to hepatocellular carcinoma-bearing mice. When the animals received microwave ablation, a technique that uses electromagnetic energy to generate lethal heat within tumor tissue, the researchers observed a striking change in the tumor-infiltrating lymphocyte population: LAG-3 expression rose on subsets of the infiltrating T cells. In other words, ablation did not merely shrink the tumor; it reshaped the immune landscape, drawing lymphocytes into the remaining tumor while simultaneously increasing the prevalence of the inhibitory checkpoint that can render those lymphocytes dysfunctional. This observation provided a mechanistic explanation for why local ablation alone often fails to prevent recurrence and why pairing it with checkpoint blockade could be advantageous.

LAG-3, or lymphocyte-activation gene 3, has attracted intense interest in oncology because it regulates T cell exhaustion through pathways that are distinct from those of the better-known checkpoint molecules PD-1 and CTLA-4. By binding its ligands and transmitting inhibitory signals, LAG-3 dampens the proliferative and cytotoxic capacity of T cells. Blocking LAG-3 with antibodies releases this brake, and several anti-LAG-3 agents are already in clinical development for solid tumors and hematologic malignancies. The new study asked a specific and clinically important question: does LAG-3 blockade complement microwave ablation in hepatocellular carcinoma, and if so, through what molecular circuitry?

The answer, according to the mouse experiments, is a clear yes. Compared with either microwave ablation or anti-LAG-3 therapy alone, the combined treatment produced a synergistic anti-tumor effect. Mice receiving both interventions survived significantly longer and showed markedly inhibited tumor growth. Beyond the gross measures of tumor burden, the combination also remodeled the tumor immune microenvironment in ways that favored immune attack: tumor-infiltrating lymphocytes increased in number, serum levels of CXCL10 rose, the population of CXCR3-positive CD8+ T cells expanded, and the cytotoxic activity of CD8+ T cells was enhanced. The convergence of increased chemokine production with greater numbers of chemokine-receptor-bearing killer cells suggested that the CXCL10/CXCR3 axis was the engine driving the therapeutic synergy.

To confirm that the chemokine axis was genuinely required rather than merely correlated, the researchers performed two decisive loss-of-function experiments. First, they blocked CXCL10 in mice receiving the combined therapy. Neutralizing the chemokine weakened CD8+ T cell function, demonstrating that the chemokine signal is necessary for the enhanced cytotoxic response. Second, they depleted or blocked CD8+ T cells themselves under the combined regimen. This maneuver promoted tumor growth and impaired the anti-tumor benefit, establishing CD8+ T cells as the essential cellular mediators of the combination effect. Together, the two experiments trace the causal chain: microwave ablation and LAG-3 blockade act together to elevate CXCL10, CXCL10 engages CXCR3 on CD8+ T cells to recruit and activate them, and activated CD8+ T cells execute the tumor killing.

The mechanistic picture is biologically plausible and fits with established immunology. Thermal injury from ablation is known to release tumor antigens and danger signals that provoke local inflammation, and inflammatory cytokines such as interferon-gamma induce CXCL10 production in stromal and immune cells. At the same time, the influx of newly activated T cells into this inflammatory environment creates a larger pool of cells vulnerable to LAG-3-mediated inhibition, which likely explains why LAG-3 expression climbed on tumor-infiltrating lymphocytes after ablation in the study. Removing that constraint with an anti-LAG-3 antibody allows the newly recruited CD8+ T cells to proliferate, produce cytotoxic molecules such as granzyme B, and sustain their attack on residual tumor cells, including microscopic deposits that ablation cannot physically reach.

Hepatocellular carcinoma remains one of the most lethal and rapidly increasing cancers worldwide, frequently diagnosed at an advanced stage when curative resection or transplantation is no longer feasible. Immune checkpoint inhibitors have transformed the treatment landscape in recent years, but only a fraction of patients respond durably, and resistance remains a central clinical problem. Locoregional therapies such as microwave ablation are standard of care for early-stage disease, yet recurrence is common. A regimen that combines the antigen-releasing and inflammation-generating effects of ablation with checkpoint blockade that preserves T cell function could address both limitations simultaneously, converting an otherwise localized treatment into an in situ cancer vaccine while ensuring the recruited immune cells retain full killing capacity.

The authors emphasize that the therapeutic potential of combining microwave ablation with LAG-3 blockade had already been demonstrated in various cancers, but its specific efficacy and molecular mechanisms in hepatocellular carcinoma had remained unclear. By identifying the CXCL10/CXCR3 pathway as the mechanistic bridge, the study fills that gap and provides biomarkers that could be used to monitor or stratify patients. Serum CXCL10 levels, the frequency of CXCR3-positive CD8+ T cells, and LAG-3 expression on tumor-infiltrating lymphocytes are all measurable in clinical settings and could serve as pharmacodynamic indicators of whether the combination is engaging its intended immune circuitry in human trials.

The study was supported by the Natural Science Foundation of Hainan Province, and all animal procedures were approved by the Animal Care and Ethical Standards Committee of Central South University Xiangya School of Medicine Affiliated Haikou Hospital. The authors declared no competing financial interests. As with any preclinical finding, important caveats apply before the results can inform patient care. Mouse models of hepatocellular carcinoma do not fully recapitulate the immunosuppressed, cirrhotic, hepatitis- or metabolically driven liver environment in which human tumors arise, and the dosing, timing, and sequencing of ablation relative to checkpoint blockade will require careful optimization in clinical studies. Nevertheless, the identification of a defined chemokine-dependent mechanism gives the field a concrete target around which to design combination trials, and it reinforces a growing consensus in immuno-oncology: the most effective treatments will be those that simultaneously generate the raw materials of an immune response and remove the brakes that prevent that response from succeeding.

Liver transplantation remains the gold standard curative option for HCC because it concurrently eliminates both the primary tumor and the cirrhotic liver milieu that fuels oncogenesis. Nonetheless, stringent transplant selection criteria—most notably, the Milan criteria—exclude many patients whose tumor burden exceeds accepted thresholds. While locoregional therapies such as transarterial chemoembolization (TACE), radioembolization, and ablation have been employed with variable success to downstage tumors and serve as bridging interventions during organ wait times, their limitations underscore an urgent need for more efficacious systemic approaches. Immune checkpoint blockade agents targeting PD-1/PD-L1 and CTLA-4 pathways have demonstrated durable responses in advanced HCC, raising the provocative question of whether these agents could be strategically employed earlier in the disease course to optimize transplantation candidacy.

The review originates from a multidisciplinary team based at the Liver Transplant and Hepatobiliary Surgery Program at Mount Sinai’s Recanati/Miller Transplantation Institute, synthesizing findings from clinical trials, large cohort studies, meta-analyses, and case series published through August 2025. The focal point lies on the therapeutic potential of ICIs used in the neoadjuvant (pre-transplant) and adjuvant (post-transplant) settings, weighing their impact on tumor control and graft immunologic outcomes—the latter being a critical barrier given the pro-inflammatory milieu unleashed by ICIs. The analysis brings to light a nuanced paradigm where immunotherapy can augment tumor downstaging and bridging but simultaneously imposes heightened risks of allograft rejection, mandating a delicate balance informed by real-world patient data.

Neoadjuvant ICI therapy prior to liver transplantation has yielded promising oncologic responses in select patient cohorts. Early-phase trials and multicenter observational studies report downstaging success rates in the range of 75% to 82%, with radiologic tumor responses approaching 94% and pathologic complete or major responses noted between 35% and 88%. These impressive figures are mirrored by favorable survival outcomes, as one-year post-transplant survival reaches approximately 95%, and three-year survival stabilizes between 70% and 80%. Importantly, long-term graft survival also remains robust, exceeding 85% at three years following transplantation with prior ICI exposure. These data collectively suggest that ICIs can enhance transplant eligibility among patients who would otherwise be excluded due to tumor burden or progression during waiting periods.

However, the immunologic repercussions of neoadjuvant immunotherapy are far from insignificant. A significant proportion of transplanted patients who received ICIs preoperatively experienced episode rates of acute rejection ranging from 16% to 28% in expansive published series. A meta-analysis aggregating individual patient data further delineated a rejection incidence of 26.4%, underscoring that immune activation by checkpoint blockade can precipitate graft immune attack. The authors underscore washout interval—the duration between the final ICI dose and the transplantation procedure—as a pivotal determinant of rejection risk. Intervals shorter than 30 to 90 days correlate with markedly elevated rejection rates, implying that a prudent, rigid washout timeframe is indispensable to mitigating immune-mediated graft injury.

In contrast, evidence for the safety and efficacy of adjuvant ICIs administered after liver transplantation remains scarce and inconclusive. Most of the current knowledge base stems from isolated case reports detailing the post-transplant administration of ICIs intended to reduce recurrence risk. Alarmingly, rejection episodes have been reported in approximately 25% of these cases, accompanied by mortality rates estimated between 10% and 12%, reflecting the treacherous immunologic landscape in the context of graft tolerance. These findings accentuate the need for translational research to elucidate immune mechanisms post-transplant and to develop safer immunomodulatory strategies that balance antitumor efficacy with graft preservation.

The review’s authors emphasize a paradigm shift: the pivotal clinical question is no longer whether neoadjuvant immunotherapy has efficacy before transplantation but how to deploy it safely within a stringent clinical framework. Implementing ICIs as a bridging modality necessitates treatment in high-volume, experienced transplant centers where multidisciplinary teams vigilantly assess tumor biology, immune status, and treatment response. Continuous monitoring of biomarkers such as alpha-fetoprotein (AFP) levels and serial imaging is paramount to evaluating therapeutic effectiveness and timing transplantation appropriately. Furthermore, fine-tuning immunosuppressive regimens post-transplant in patients with prior immune checkpoint blockade exposure is crucial to minimize rejection risk without compromising antitumor surveillance.

The implications of these insights extend beyond individual patient management to systemic transplant policy and oncology care pathways. If prospective randomized controlled trials validate neoadjuvant immunotherapy as a safe and effective strategy, it could redefine transplant eligibility criteria and reduce the high dropout rates experienced on waiting lists due to tumor progression. Conversely, post-transplant immunotherapy, while conceptually attractive for curtailing tumor recurrence, requires further validation and innovation to overcome significant hurdles related to graft rejection and toxicity.

Alternative immune-based therapies such as natural killer (NK) cell adoptive transfer and cytokine-induced killer (CIK) cells emerge as promising avenues that might confer antitumor benefits with potentially lower risk of graft rejection. These approaches exploit innate immune effector functions and cytokine milieus that may preserve graft tolerance more effectively than T-cell checkpoint blockade. As such, combinatorial or sequential immunotherapeutic strategies integrating these modalities could become an integral component of personalized HCC management pre- and post-liver transplantation.

In summary, the integration of ICIs into the liver transplantation pathway for hepatocellular carcinoma represents a landmark advance fraught with significant clinical challenges. The precision application of neoadjuvant immunotherapy can expand curative therapeutic options for HCC patients otherwise ineligible for transplantation, but only under rigorous clinical protocols that optimize timing and patient selection while safeguarding graft survival. Post-transplant immunotherapy still demands cautious exploration given the heightened risk profile. This evolving field calls for robust clinical trials, translational immunologic research, and collaboration among oncologists, hepatologists, and transplant surgeons to fully harness the transformative potential of immunotherapy in HCC.

As immunotherapeutic strategies mature, they hold the promise to not only enhance survival outcomes for HCC patients but also to revolutionize transplant oncology by shifting paradigms toward precision immunomodulation. Balancing the dual imperatives of tumor eradication and graft protection will remain the crux of innovation, heralding a future where immunotherapy adjuncts expand the frontiers of curative liver transplantation with safety and efficacy at the forefront.

Subject of Research: Not applicable

Article Title: Hepatocellular carcinoma and liver transplant: What about neo- and adjuvant immunotherapy

News Publication Date: 16-Jun-2026

Web References: https://doi.org/10.1016/j.hbpd.2025.10.004

References: 10.1016/j.hbpd.2025.10.004

Keywords: Adjuvants, Immune checkpoint inhibitors, Hepatocellular carcinoma, Liver transplantation, Neoadjuvant therapy, Adjuvant therapy, Immunotherapy, Tumor downstaging, Graft rejection, Alpha-fetoprotein, Locoregional therapy, NK cell therapy

Transarterial chemoembolization (TACE) has long been a cornerstone of the treatment protocol for unresectable HCC. This technique involves the selective delivery of chemotherapeutic agents directly into the hepatic artery, coupled with embolic agents that occlude blood flow to the tumor. However, traditional outcomes often fell short, warranting the exploration of adjunctive therapies aimed at enhancing efficacy. The integration of immune checkpoint inhibitors and molecular targeted therapies represents a promising avenue to bolster the clinical outcomes for patients receiving TACE.

The field of immunotherapy has transformed cancer treatment paradigms over the past decade. Immune checkpoint inhibitors, designed to unshackle the immune system’s ability to recognize and destroy cancer cells, have shown promise across a spectrum of malignancies. Combining this modality with TACE could potentially activate a dual mechanism — while TACE disrupts the tumor’s microenvironment, immune checkpoint inhibitors boost the systemic immune response against residual disease. This strategy harbors the potential for synergistic effects, particularly in older adult patients whose immune systems are generally compromised yet can still respond to therapeutic interventions.

Furthermore, molecular targeted therapies — designed to disrupt specific pathways critical to cancer cell survival and proliferation — can enhance the overall treatment modality. By modulating key molecular targets, these therapies can lead to apoptosis, a programmed cell death that is critical for effective tumor regression. This multi-faceted approach of combining TACE with both immunotherapy and targeted therapies could result in an amplified response in older adults battling unresectable HCC, providing a much-needed lifeline in a patient population often underrepresented in clinical trials.

The research conducted by Hong and colleagues sheds light on the complexities involved in administering combination therapy to older adults. It meticulously assesses the safety profile, evaluating adverse events related to the treatment protocols. Given the often precarious health status of older patients, understanding the balance between treatment efficacy and potential side effects is paramount. The study highlights not only the clinical outcomes but also the importance of safeguarding the patients’ quality of life, ensuring that any treatment regimen maintains their functional status while combating the disease.

As the landscape of cancer therapeutics continues to evolve, the inclusion of older adults in clinical research becomes ever more essential. Historical trends have shown a systematic underrepresentation of this demographic in trials, resulting in treatment protocols that may not fully address their unique needs and challenges. This research stands as a beacon for future studies, advocating for a paradigm shift that cultivates inclusivity in clinical trials, thereby enhancing treatment options for older patients diagnosed with cancers like HCC.

In the study, the investigators employed rigorous methodologies to appraise both safety and efficacy. This encompassed a thorough evaluation of clinical endpoints, including overall survival rates, progression-free survival, and complete response rates. In addition, patient-reported outcomes pertaining to symptoms, side effects, and quality of life metrics were collected, emphasizing a holistic view of treatment effects. This intricate data collection serves to inform not only clinical practice but also future directions in research.

The findings from this study have profound implications for oncologists, particularly those specializing in hepatobiliary tumors. With a growing elderly population at risk for HCC, the need for tailored, effective treatment strategies is pressing. Oncologists must remain abreast of the latest advancements in combination therapy to offer patients the most current and evidence-based management options. The study elucidates the potential for TACE in synergy with immunotherapies and molecular therapies, paving the way for improved treatment protocols.

Moreover, adherence to treatment protocols in older adults is a significant concern, as polypharmacy and other health complications can affect treatment completion. This research highlights the importance of designing comprehensive care plans that are not only effective but are also feasible given the complexities that accompany older age. Ensuring that healthcare teams are equipped to navigate these challenges will be essential for the successful implementation of new treatment regimens.

Despite the promising outcomes observed in the study, it is crucial to maintain a dialogue about the long-term implications of combining these modalities. The intricacies of the immune system, particularly in older individuals, necessitate continued investigation into the optimal timing and dosing of these therapies. Research must continue to ascertain the durability of responses in patients receiving combination therapy, ensuring that the benefits continue to outweigh any associated risks.

Patient education and shared decision-making form the bedrock of cancer care, especially when innovative therapies are introduced. The complexities of TACE combined with checkpoint inhibitors and targeted therapies require clear communication between physicians and patients. This study emphasizes the importance of engaging patients in their treatment journey, discussing potential side effects and realistic expectations while providing hope through emerging treatment strategies.

Finally, as the healthcare community embraces the insights gathered from this groundbreaking research, collaborative efforts will be essential to further refine treatment avenues for older adults with unresectable HCC. Cross-disciplinary partnerships among oncologists, researchers, geriatric care specialists, and policymakers will foster an environment conducive to advancing research and facilitating the approval of new therapeutic strategies.

In conclusion, the amalgamation of TACE with immune checkpoint inhibitors and molecular targeted therapies offers a beacon of hope in treating older adults with unresectable hepatocellular carcinoma. As the scientific community continues to unravel the complexities of cancer treatment in this vulnerable population, the findings presented by Hong and colleagues provide a springboard for future research and clinical application. The unveiling of improved treatment protocols promises to enhance survivorship and quality of life for many, marking a vital step forward in the relentless fight against cancer.

Subject of Research: Hepatocellular carcinoma treatment in older adults

Article Title: Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma.

Article References:

Hong, X., Huang, JT., Hu, D. et al. Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma.
J Cancer Res Clin Oncol 151, 202 (2025). https://doi.org/10.1007/s00432-025-06257-z

Image Credits: AI Generated

DOI: 10.1007/s00432-025-06257-z

Keywords: hepatocellular carcinoma, TACE, immune checkpoint inhibitors, molecular targeted therapies, older adults, oncology, combination therapy, safety and efficacy, survivorship.